Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma

We studied all patients at our institution with a diagnosis of multiple myeloma (MM), from 1 January 2004 to 1 July 2009, who received lenalidomide–dexamethasone (Rd) as initial therapy and had a time to progression of 72 months or longer. Of 240 patients, we identified 33 exceptional responders. Tw...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Cancer J
Main Authors: Vu, T, Gonsalves, W, Kumar, S, Dispenzieri, A, Lacy, M Q, Buadi, F, Gertz, M A, Rajkumar, S V
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4635199/
https://ncbi.nlm.nih.gov/pubmed/26495860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2015.91
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados